Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson’s Disease

In a recent study, we described the neuroprotective properties of VCE-003.2—an aminoquinone derivative of the non-psychotropic phytocannabinoid cannabigerol (CBG)—administered intraperitoneally (i.p.) in an inflammatory model of Parkinson’s disease (PD). We also demonstrated that these properties de...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgaz, Sonia, García, Concepción, Gómez-Cañas, Maria, Muñoz, Eduardo, Fernández-Ruiz, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696432/
https://www.ncbi.nlm.nih.gov/pubmed/31349553
http://dx.doi.org/10.3390/molecules24152702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696432/
https://www.ncbi.nlm.nih.gov/pubmed/31349553
http://dx.doi.org/10.3390/molecules24152702

Ejemplares similares